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We provide in this paper a detailed characterization of the human peripheral CD4 þ CD127 low CD25 þ regulatory T cell (Treg) compartment, with a particular emphasis in defining the population expressing higher levels of the IL-6 receptor (IL-6R). We provide a description of the phenotype of this population by assessing both the surface expression by flow cytometry as well as their transcriptional profile and functional features. In addition, we also present functional data describing the responsiveness of these subsets to IL-6 signalling in vitro and to IL-2 in vivo. The data presented in this paper support the research article "Human IL-6R Flow cytometry and gene expression profiling was performed in freshly isolated PBMCs or CD4 þ T cells. Cytokine production was assessed following in vitro stimulation with PMA þ ionomycin. Cell proliferation was assessed by flow cytometry by culturing cells in vitro with anti-CD3/anti-CD28 stimulation.
Experimental features
Delineation of the Treg compartment was performed in human peripheral blood cells using polychromatic flow cytometry. The global transcriptional profile of the assessed T cell subsets was assessed in sorted cells isolated ex vivo.
Data source location
Samples from human volunteers and T1D patients were collected in Cambridge, UK. Data accessibility All primary non-clinical data are available in this article. The DILT1D data from individuals prior to normalization as a group are available, however they cannot be anonymized sufficiently to be able to put into the public domain without risk of participant identification. Data are available on request, through the Cambridge University institutional repository (DOI link: https://doi.org/10.17863/CAM.832).
Related research article
The data presented in this paper support the research article "Human IL-
þ T cells display potent in vitro suppressive capacity and a distinct Th17 profile" (Ferreira RC et al., 2017 ) [1] .
Value of the data
Data provide a detailed description of the human peripheral Treg compartment at both the protein and transcriptional level.
The flow cytometry data provides a valuable resource for other researchers to compare the expression levels of a number of classical Treg surface markers within the defined CD4 þ T cell populations defined here.
The detailed information on the flow cytometry antibodies and polychromatic panel combinations will be a valuable tool for researchers in the field to help design their specific immunostaining panels.
Cell subset heterogeneity is one of the main challenges in the description of human Treg populations, and is clearly highlighted in the data presented in this paper.
Data provide precise quantitative information regarding the expression levels of a broad range of immune genes at the mRNA level in highly purified human Treg subsets both ex vivo and after in vitro stimulation.
Data
The dataset contained in this article provides a detailed characterization of the expression of the IL-6 receptor (IL-6R) on circulating human CD4 þ CD127 low CD25 high T cells ex vivo. These data also provide a functional characterization of the assessed T cell subsets, with a particular emphasis on a subset of IL-6R hi regulatory T cells (Tregs) lacking the expression of the co-inhibitory receptor TIGIT.
The Fig. 1 and Fig. 2 depict the delineation of the assessed immune subsets and their responsiveness to IL-6 signalling. Fig. 3 depicts data from a clinical study investigating the responsiveness of the assessed T cells subsets to IL-2 signalling in vivo. Fig. 4 depicts the proliferative capacity of the Treg subsets in vitro, in the absence of exogenous IL-2. Fig. 5 and Fig. 6 depict the expression at the protein level of Th17 surface markers. Fig. 7 depicts the differential mRNA expression of 579 immune genes between IL-6R hi TIGIT À and IL-6R hi TIGIT þ Tregs. Fig. 8 , Fig. 9 and Fig. 10 depict the immunophenotyping of the Th17 transcription factor RORγt, and different tissue-homing receptors at the protein level. Fig. 11 depicts the expression of two cytokines, IL-17 and IL-10, in TIGIT þ Tregs and Fig. 12 depicts the variation of HELIOS -TIGIT -and HELIOS þ TIGIT þ Tregs measured by intracellular flow cytometry on cryopreserved peripheral blood mononuclear cells (PBMCs) on 8 selected patients from the DILT1D clinical study. Table 1 provides the complete information on the fluorochrome-conjugated antibody panels used in tis study, and Table 2 and Table 3 contain the complete gene expression data of 579 immune genes on the assessed T cell subsets, obtained in ex vivo-isolated cells or following in vitro stimulation, respectively.
Experimental design, materials and methods

Patient selection
Patient selection and the protocol for the "Adaptive study of IL-2dose on regulatory T cells in type 1 diabetes" (DILT1D) has been published previously [2, 3] . A subset of 22 T1D patients (median age ¼ 26, range 18-48) were selected for this study, and assessed for the expression of IL-6R on Tregs. A blood sample was taken before treatment to establish baseline Treg frequencies and phenotypes, followed by subcutaneous administration of a single dose of recombinant human IL-2 (Proleukin/ aldesleukin; dose range 45,000-737,000 IU/m2) on day 0. The patients were bled 90 min after treatment, and then daily to day 4 and at days 7, 9, 14, 21 and 60.
Study participants for all further immunophenotyping and functional assays included in this study were adult healthy volunteers recruited from the Cambridge BioResource (http://www.cambridgebioresource. org.uk/). All samples were collected after approval from the relevant research ethics committees, and written informed consent was obtained from the participants.
Flow cytometry
Treg immunophenotyping in healthy donors was performed in fresh peripheral blood mononuclear cells (PBMCs) isolated by Ficoll gradient centrifugation (Lymphoprep; STEMCELL Fig. 1 ). The maximum increases over the baseline pre-treatment frequencies achieved during the course of the study are indicated for each IL-2 dosing group. P values for the maximum increase in the frequency of the assessed parameter in response to a single dose of IL-2 was calculated using a two-tailed paired non-parametric Wilcoxon signed rank test comparing the frequencies observed at the timepoint where the maximal increase was achieved with the respective baseline pre-treatment frequencies. P values for the IL-2 dose-dependent effects were calculated using a two-tailed non-parametric a two-tailed non-parametric Mann-Whitney test comparing the frequency of IL-6R hi cells between the low and high dose groups at each timepoint. The DILT1D data from individuals prior to normalization as a group are available, however they cannot be anonymized sufficiently to be able to put into the public domain without risk of participant identification. Data are available on request, through the Cambridge University institutional repository (DOI link: https://doi.org/10.17863/CAM.832). *P o 0.05; **P o 0.01; ns ¼ not significant.
Technologies) from whole blood within 2 h of phlebotomy. Cells were stained with fluorochromeconjugated antibodies against surface receptors (see Table 1 for details) for 45 min at 4°C. Fixation and permeabilisation was performed using FOXP3 Fix/Perm Buffer Set (BioLegend) and cells were then stained with the respective intracellular antibodies for 45 min at room temperature (Table 1) . For the DILT1D clinical trial participants, 30 ml whole blood were collected into lithium heparin tubes and processed within 4 h of phlebotomy. Immunostaining was performed in whole blood with specific fluorochrome-conjugated antibodies (listed in Table 1 ) at room temperature for 45 min. IL-6R expression was assessed using a phycoerythrin (PE)-conjugated antibody, which provided the better resolution in our flow cytometric setting. This was critical to increase the sensitivity of the assay, and assess quantitative differences in IL-6R expression in different T cell subsets. . P values were calculated using a two-tailed paired non-parametric Wilcoxon signed rank test.
Cell sorting
Cell sorting was performed using a BD FACSAria Fusion flow cytometer (BD Biosciences) after preenrichment of CD4 þ T cells from whole blood by negative selection. Fluorescence-conjugated antibodies used for sorting are described in Table 1 . Sorting efficiencies were determined in four donors, based on IL-6R and TIGIT expression and ranged between 90-99%.
Intracellular pSTAT3 immunostainings
PBMCs were isolated from three healthy donors by Ficoll gradient centrifugation from whole blood within 2 h of phlebotomy. IL-6 sensitivity of the memory Treg and Teff subsets was determined by intracellular pSTAT3 immunostaining in freshly isolated PBMCs in response to IL-6 stimulation in vitro, as previously described [6] . 
in vitro proliferation assays
To assess the proliferative capacity of IL-6R hi TIGIT À , IL-6R hi TIGIT þ and IL-6R lo TIGIT þ Tregs and memory Teffs, 10 4 sorted cells from each subset were labelled with eFluor450 Cell Proliferation Dye (eBioscience), and cultured in the presence of exogenous IL-2 (100 U/ml; Proleukin) and anti-CD3/ CD28 activation beads, at a 1:1 bead:Teff ratio in X-VIVO 15 þ 5% human AB serum. Cells were cultured in X-VIVO 15 þ 5% human AB serum for 84 h at 37°C in V-bottom 96-well cell culture plates (CELLSTAR, Greiner) in the presence of exogenous IL-2 (100 U/ml; Proleukin) and anti-CD3/CD28 activation beads (Life Technologies), at a 1:1 bead:Teff ratio. Proliferation of the responder cells was assessed by the dilution of the proliferation dye by flow cytometry. Proliferation capacity was calculated using the Division Index (DI) in FlowJo (Tree Star). The DI represents the average number of cell divisions that each seeding Teff cell has undergone and was obtained using the following equation: DI ¼ Total number of Cell Divisions / Initial number of Teff cells in culture ¼
, where n represents the number of divisions and G (n) represents the number of cells that have undergone n divisions. 
Cytokine secretion assays
To assess cytokine production, CD4 þ T cells were isolated from whole blood by negative selection using RosetteSep (STEMCELL Technologies) within 2 h of phlebotomy. Cells were resuspended in X-VIVO 15 (Lonza) þ 5% heat-inactivated, filtered human AB serum (Sigma), and cultured (1-2 Â 10 6 CD4s/well) in a 24-well flat-bottom cell culture plate (CELLSTAR, Greiner) at 37°C in the presence or absence of the 1X Cell Stimulation Cocktail (eBiosiences), containing phorbol myristate acetate (PMA), ionomycin, and protein transport inhibitors (brefeldin A and monensin). After 6 h culture, cells were harvested and immunostained with surface and intracellular antibodies (listed in Table 1 ). The unstimulated cells were used to determine background levels of cytokine production. Dead-cell exclusion was performed using the eFluor780 Fixable Viability Dye (eBiosciences). 
Transcriptional profiling of the Treg subsets
Gene expression profiling was performed by NanoString, using the pre-designed nCounter Human Immunology v2 Panel (NanoString Technologies). The four assessed immune cell subsets were flow sorted as described above, and 25,000 cells were collected into RLT lysis buffer (Qiagen) either: (i) directly ex vivo; or (ii) following in vitro stimulation for 165 min in the presence or absence of 50 ng/ml PMA (Sigma-Aldrich) and 500 ng/ml ionomycin (Sigma-Aldrich), without addition of protein transport inhibitors. RNA from the flow-sorted T cell subsets was extracted using the RNAeasy Micro Plus kit (Qiagen), with gDNA cleanup, following manufacturer's instructions. Total RNA samples were then hybridized to the NanoString CodeSets, following manufacturer's instructions. Expression levels were assessed using an nCounter Flex instrument (NanoString Technologies). Data were processed using the nSolver Analysis Software following normalization of the raw read counts to the geometric mean of positive control spike-ins, and the gene expression of 15 selected housekeeping genes (ATG10, C14orf166, CD3E, CD46, G6PD, GPI, POLR1B, POLR2A, PSMB5, PSMB10, PTPRC, SDHA, SKI, TOLLIP and TUBB) that were found to have low variability on both the samples collected ex vivo and following in vitro stimulation.
Statistical analyses
Statistical analyses were performed using Prism software (GraphPad) and R (www.r-project.org. com). Statistical significance was assessed using a two-tailed non-parametric Mann-Whitney test.
Comparison of immune phenotypes between the assessed Treg subsets from the same individual was performed using a two-tailed paired non-parametric Wilcoxon signed rank test. 
þ T cells; and in memory T effector cells.
Differential expression of normalized NanoString transcriptional data was calculated using a paired analysis with DESeq. 2 v1.12.3 [7] , with pre-set size factors equal to one for all samples. Adjusted P values correspond to the false discovery rates (FDR) for differential expression, computed after correcting P values for multiple testing. A missing FDR is reported for genes that were found to contain an expression outlier by DESeq. 2 Cook's distance-based flagging of P values, and thus excluded from multiple testing. depicted in black); or (ii) the higher IL-2 doses of 0.6-1.5 x 10 6 U/ml (N ¼ 6; depicted in red). Data were obtained from intracellular staining of cryopreserved PBMCs from eight selected T1D patients enrolled in the "Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes" (DILT1D). The DILT1D data from individuals prior to normalization as a group are available, however they cannot be anonymized sufficiently to be able to put into the public domain without risk of participant identification. Data are available on request, through the Cambridge University institutional repository (DOI link: https://doi.org/10. 17863/CAM.832). 
